|0.761 0 (0%)||12-01 15:39|
|Targets||6-month :||1.96||1-year :||2.75|
|Resists||First :||1.68||Second :||2.36|
|Supports||First :||0.57||Second :||0.48|
|MAs||MA(5) :||0.78||MA(20) :||0.82|
|MA(100) :||2.4||MA(250) :||2.23|
|MACD||MACD :||-0.3||Signal :||-0.4|
|%K %D||K(14,3) :||37.8||D(3) :||38.2|
|52-week||High :||6.9||Low :||0.57|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CWBR ] has closed above bottom band by 45.8%. Bollinger Bands are 61.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||0.74 - 0.74||0.74 - 0.75|
|Low:||0.64 - 0.64||0.64 - 0.65|
|Close:||0.66 - 0.67||0.67 - 0.68|
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||3 (M)|
|Shares Float||2 (M)|
|Held by Insiders||15 (%)|
|Held by Institutions||2.5 (%)|
|Shares Short||19 (K)|
|Shares Short P.Month||29 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||3.26|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-48.4 %|
|Return on Equity (ttm)||-84 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-8 (M)|
|Levered Free Cash Flow||-4 (M)|
|Price to Book value||0.25|
|Price to Sales||0|
|Price to Cash Flow||-0.31|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|